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Abstract
Background: Whole body fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography
(PET/CT) is the standard of care in oncologic diagnosis and staging, and patient radiation dose must be well
understood to balance exam benefits with the risk from radiation exposure. Although reference PET/CT patient
doses are available, the potential for widely varying total dose prompts evaluation of clinic-specific patient dose.
The aims of this study were to use exam-specific information to characterize the radiation dosimetry of PET/CT
exams that used two different CT techniques for adult oncology patients and evaluate the practicality of employing
an exam-specific approach to dose estimation.
Methods: Whole body PET/CT scans from two sets of consecutive adult patients were retrospectively reviewed.
One set received a PET scan with a standard registration CT and the other a PET scan with a diagnostic quality CT.
PET dose was calculated by modifying the standard reference phantoms in OLINDA/EXM 1.1 with patient-specific
organ mass. CT dose was calculated using patient-specific data in ImPACT. International Commission on
Radiological Protection publication 103 tissue weighting coefficients were used for effective dose.
Results: One hundred eighty three adult scans were evaluated (95 men, 88 women). The mean patient-specific
effective dose from a mean injected 18F-FDG activity of 450 ± 32 MBq was 9.0 ± 1.6 mSv. For all standard PET/CT
patients, mean effective mAs was 39 ± 11 mAs, mean CT effective dose was 5.0 ± 1.0 mSv and mean total effective
dose was 14 ± 1.3 mSv. For all diagnostic PET/CT patients, mean effective mAs was 120 ± 51 mAs, mean CT effective
dose was 15.4 ± 5.0 mSv and mean total effective dose was 24.4 ± 4.3 mSv. The five organs receiving the highest
organ equivalent doses in all exams were bladder, heart, brain, liver and lungs.
Conclusions: Patient-specific parameters optimize the patient dosimetry utilized in the medical justification of
whole body PET/CT referrals and optimization of PET and CT acquisition parameters. Incorporating patient-specific
data into dose estimates is a worthwhile effort for characterizing patient dose, and the specific dosimetric
information assists in the justification of risk and optimization of PET/CT.
Keywords: PET/CT, CT, Radiation exposure, Effective dose, 18F-FDG
* Correspondence: quinnb@mskcc.org
Brian Quinn is the first author.
1Department of Medical Physics, Box 84, Memorial Sloan Kettering Cancer
Center, 1275 York Avenue, New York, NY 10065, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Quinn et al. BMC Medical Imaging  (2016) 16:41 
DOI 10.1186/s12880-016-0143-y
Background
Positron emission tomography/computed tomography
(PET/CT) has become an indispensable imaging modal-
ity for the diagnosis, staging and monitoring of therapy
response of a broad range of malignancies [1, 2]. PET/
CT is a valuable tool in oncology due to the combined
metabolic and morphological information provided. The
PET emission scan provides physiological information
using a set of detectors that are independent of CT
transmission detection, and although two independent
PET and CT images may be coregistered to form a single
image, the two scans are most accurately coupled when
both are acquired during the same exam using a com-
bined PET and CT scanner. For this reason, and because
a built-in CT provides other conveniences such as at-
tenuation correction, most modern PET scanners are
dual PET/CT units. Regardless of acquisition circum-
stances, the patient dose from PET and the patient dose
from CT in PET/CT exams are first estimated separately
in different ways, and then combined to give a total
whole body radiation dose. Referral for PET/CT studies
must be justified in each case as a first general principle
of radiological protection [3]. Optimization, or ensuring
that the diagnostic information is as high as reasonably
achievable while maintaining radiation doses as low as
reasonably achievable, is the second general principle in
radiologic protection according to the International
Committee on Radiological Protection (ICRP) [4]. Add-
itionally, increased awareness of the risk of exposure to
ionizing radiation has resulted in efforts to minimize ra-
diation dose incurred during x-ray and nuclear medical
imaging tests [5]. Implementation of any dose saving
strategies depends critically on accurate dose measure-
ment/dosimetry to maximize the benefit/risk ratio from
imaging tests [6].
A reliable method of estimating patient dose, which
includes appropriate units of dose measurement and ap-
propriate calculation methods, is important for any
exam involving ionizing radiation. As Stabin stated, the
biokinetic model used to calculate the dose is one of the
major uncertainties in the evaluation of radiation doses
for radiopharmaceuticals [7]. If careful patient specific
dosimetry is performed, with attention paid to accurate
measurement of individual organ volumes, many of the
biokinetic model uncertainties can be minimized, and
the total uncertainty in the individual dose estimate can
be reduced to perhaps ±10 %-20 %[7]. Effective dose is a
parameter that allows a meaningful comparison of the
radiation dose from the radiopharmaceutical and the x-
ray portions of a PET/CT scan. Effective dose is not dir-
ectly measured, rather it is calculated based on equiva-
lent doses to organs and the radiosensitivities of the
organs. Effective dose is commonly used when evaluat-
ing relative biologic risk (4), and the Monte Carlo–based
organ dose coefficients should not be used to calculate
effective dose for individual patients [6, 8]. The Inter-
national Organization for Medical Physics, ICRP, Health
Physics Society and American Association of Physicists
in Medicine (AAPM) all have issued policy statements
that note the dangers of extrapolating biological risk es-
timates for radiation doses less than 100 mSv [6, 9–11].
The establishment and use of risk coefficients to esti-
mate public health determinants from individual or
population exposures must be considered in the context
of uncertainties in the estimates [12]. These uncertain-
ties include dosimetric uncertainties, epidemiological
and methodological uncertainties, uncertainties from
low statistical power and precision in epidemiology stud-
ies of radiation risk, uncertainties in modeling risk data,
generalization of risk estimates across different popula-
tions and dose rates, as well as reliance on epidemio-
logical studies on observational rather than experimental
data [13]. Uncertainties in such risk estimates have been
suggested as being up to a factor of 3 lower or higher
than the value itself [14]. These rather large uncertain-
ties cause predictions of radiation induced cancers or
detriment to be susceptible to biases and confounding
influences that are unidentifiable. With due recognition
of the limitations imposed by the uncertainties inherent
in correlating dose to risk, effective dose is a useful ap-
proximation for relating patient dose from internal and
external sources, evaluating population characteristics
and evaluating optimization efforts. Organ doses from
PET are estimated based on the injected activity, while
organ doses from CT are estimated based on scanner-
specific monte carlo simulations or the dose parameter
reported in the exam dose report. Both approaches can
be made to more accurately reflect the actual patient
dose by including scanner- and patient-specific factors.
Without specific information, risk evaluations may be
based on reference or literature values that must be
carefully chosen if used for risk evaluation. The Inter-
national Atomic Energy Agency’s “Radiation Protection
of Patients” (RPOP) is a reputable online reference re-
source that provides information for health healthcare
professionals, member states and the general public to
achieve safer use of radiation [15]. In the absence of spe-
cifics, reference values can overgeneralize and can result
in conservative overestimates of dose in an attempt to
account for many variables. Such generalization is inher-
ent in non-specific reference values for PET/CT exams
because of the number of PET and CT variables contrib-
uting to overall dose. CT technique differs greatly if it is
just for attenuation correction or if it is for diagnostic-
quality images. Attenuation correction can be performed
with CT currents as low as 10 mA but most institutions
use CT currents of 40-80 mA [16]. Further, an oncology
center, for example, may have an intermediate CT
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technique that provides images with better image quality
than a technique only for attenuation correction but lower
image quality than a diagnostic CT technique. PET dose
varies primarily with injected activity, but like CT dose
varies with patient size. The dependency of total dose on
many factors warrants a critical review of general reference
values and suggests the importance of specific data.
Several approaches to PET/CT dose estimation utilize
exam-specific parameters. Dose Length Product (DLP) is
a standardized CT dose parameter that is established for
each CT scanner using a phantom, equal to CTDIvol
multiplied by the length of the scan. DLP can be related
to effective dose by multiplying DLP by a patient-specific
factor, or scanner-specific monte carlo simulation data
can be employed to estimate CT dose [17, 18]. ImPACT
method calculates organ dose from CT and uses simplified
stylized anatomic models that are anatomically crude but
widely used for practical applications with the standard
mathematic representations of the reference man and
other representative phantoms in radiation protection, nu-
clear medicine, and medical imaging [19–21]. Radiophar-
maceutical organ dose is estimated utilizing conversion
coefficients and injected activity, such as those in ICRP
106. Effective dose is typically calculated from both PET
and CT organ dose utilizing tissue-weighting factors, such
as those in ICRP 103.
In these ways, effective dose from both PET and CT both
are calculated and combined to represent a whole body
burden. This combined whole body burden is useful in
evaluating both the relative and absolute benefit of the
combined scan. Although PET/CT is widely performed,
published patient dose data is as varied as the parameters
determining the dose and often focuses on a narrow patient
population [22–31]. The potential for variation in PET scan
practices and CT techniques is especially apparent when
one considers the wide range of scanner makes & models,
injected activity and patient populations in different coun-
tries. Many clinic-specific elements that influence radiation
dose can be incorporated into the dose estimate to make
the dose more specific to the patient.
The aim of the present study was to characterize the
radiation dosimetry of two types of routine whole body
PET/CT protocols at our institution using patient-specific
data and commonly available dose estimation techniques.
We compare the results of using patient-specific data with
reference and published values and ascertain the utility of
such data in the evaluation of risk/benefit for justification
and protocol optimization in routine clinical utilization.
Methods
Study population
Institutional review board approval with waiver of pa-
tient informed consent was obtained to perform a retro-
spective study of clinically indicated whole body PET/
CT scans performed on consecutive adult oncology
patients at Memorial Sloan Kettering Cancer Center
from January 2010 through December 2011. Patient con-
sent was not required.
Patient population data
Consecutive adult patients who had undergone PET/CT
with either standard registration or full dose diagnostic
quality CT techniques for a variety of oncological indica-
tions, were identified. Patient demographics are shown
in Table 1.
Exam data
For each PET exam performed, the amount of 18F-FDG
administered was obtained from the medical records.
For each CT study, image data was reviewed to deter-
mine the body region that was being examined, and this
was repeated for each CT series. The following parame-
ters for each series were extracted from the DICOM
headers, dose reports and scan scout images for later
organ equivalent dose and effective dose calculation: (a)
kVp, (b) mA, (c) beam collimation, (d) rotation time, (e)
pitch, (f ) volume CT dose index (CTDIvol) and (g) dose
length product (DLP).
18F-FDG PET/CT exam
All whole-body PET/CT patients fast for at least 6 h,
blood glucose concentration is determined before the
injection of the radiopharmaceutical. A nominal injec-
tion activity of 12 mCi (444 MBq) is prescribed in our
clinic, and +/- 10 % of the prescribed activity is actually
injected intravenously into the patient. The actual
injected activity is recorded for each patient. Following
an approximately 60 min uptake time, PET/CT exams
are performed on General Electric (GE) scanners. Data
for this study were recorded from patients scanned on
Discovery 690 DSTE PET/CT, which utilizes a GE Light-
speed 16 CT scanner (GE Healthcare, Milwaukee, Wis).
Tube current modulation is utilized for all CT acquisi-
tions except the “scout” scan, which uses a fixed tech-
nique of 120 kVp, 10 mA, pitch 3 and rotation time
0.5 s. The first part of the exam sequence is acquisition
of a scout CT image used to select the desired anatomy
to be scanned and establish bed positions for PET acqui-
sition. The technologist selects from base of the skull to
Table 1 Patient demographics
No.
patients
Age Body mass index
Yrs
Male 95 53.7 ± 18.1 (18.8–90.2) 26.2 ± 4.8 (15.1–46.1)
Female 88 52.1 ± 20.3 (18.4–96.7) 26.6 ± 7.8 (15.6–71.5)
Male and female 183 52.3 ± 19.3 (18.4–96.7) 26.4 ± 6.4 (15.1–71.5)
All data are mean ± standard deviation (range)
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mid thighs for body PET/CT scans. Next a CT scan is
acquired using either the standard or the diagnostic CT
technique, depending on the required patient specific
protocols completed by the radiologist. The technique
for all standard PET/CT exams in this study is 120 kVp,
auto-mA, rotation time 0.8 sec, slice thickness 3.75 mm,
collimator width 10 or 40 mm, pitch 1.75. The technique
for all PET/CT exams with a diagnostic CT is 120 kVp,
auto-mA, rotation time 0.6 s, slice thickness 5.00 mm,
collimator width 20 or 40 mm, pitch 1.375. CT tech-
niques are summarized in Table 2.
CT is followed immediately by PET acquisition with a
3-min emission acquisition time per bed position, a
15.3-cm axial field of view per bed position with a 23 %
bed overlap.
Internal radiation-absorbed dose assessment
The OLINDA\EXM code (version 1.1, Vanderbilt
University, Nashville, TN, USA) was used to determine
the organ equivalent dose and effective dose from each
PET series with patient-specific parameters [32]. The bio-
kinetic model parameters as defined in Bolch et al (2009)
and specifically identified in ICRP Publication 106 for
18F-FDG were used as input factors for OLINDA [33, 34].
The ICRP biokinetic model for 18F-FDG was derived
from data in Hayes et al and Deloar et al [35, 36]. The
OLINDA code also allows for the modification of standard
reference phantoms to more closely represent patient-
specific factors, such as patient weight and corresponding
organ mass. We used the standard anthropomorphic
models as well as models modified to represent patients
weight and height (i.e., organ sizes of the phantom models
used by OLINDA were modified to reflect the patient-
specific mass of the organ as described by Marine et al
and Clark et al [37–39]. Modified adult male, adult female
models in OLINDA’s phantom library were utilized to
generate patient-specific organ equivalent dose, and then
tissue weighting factors from ICRP Publication 103 were
used to generate patient-specific effective dose conversion
factor (mSv/MBq) [6]. These factors were multiplied by
injected activity (MBq) for each PET study to obtain an es-
timation of effective dose.
External radiation-absorbed dose assessment
Effective dose from CT examination was estimated using
the CT-specific method using the ImPACT spreadsheet,
employing ICRP 103 weighting factors [17].
Statistical analysis
Descriptive and summary statistics were performed
with a spreadsheet application (Excel 2007, Microsoft,
Redmond, WA). Statistical analysis included average,




Of the total 183 PET/CT scans evaluated, 95 (52 %) were
performed on male patients and 88 (48 %) were per-
formed on female patients. Forty-six male patients and
39 female patients received the standard CT technique.
Forty-nine male patients and 49 female patients received
the diagnostic CT technique. Subjects ranged in age
from 18 to 96 years (mean ± standard deviation (SD)
52.6 ± 18.2 years). The subjects’ weight ranged (mean ±
SD) from 42.0 to 182 kg (74.9 ± 17.7 kg), height ranged
(mean ± SD) from 120 to 198 cm (168 ± 10.3 cm), and
BMI ranged (mean ± SD) from 15.1 to 71.5 (26.4 ± 6.4).
18F-FDG
The mean ± SD (range) 18F-FDG injected activity for all
patients was 454 ± 33.3 MBq (152 to 488 MBq).
CT techniques
The mean ± SD (range) effective mAs of the standard
CT for all patients was 39.0 ± 11.2 mAs (27.4 to 69.4
mAs), 38.6 ± 10.0 mAs (27.4 to 69.4 mAs) for male
patients and 39.4 ± 12.4 mAs (27.4 to 69.4 mAs) for
female patients.
The mean ± SD (range) effective mAs of the diagnostic
CT for all patients was 119 ± 50.6 mAs (27.4 to 231 mAs),





Tube current Revolution time Collimator
width
Pitch Effective mAsa CTDIvol DLP Effective Dose Effective dose
per unit mAs
(kVp) (mA) (s) (mm) (mGy) (mGy cm) (mSv) (mSv/mAs)
Standard male 120 78 ± 8.2 0.8 10 or 40 1.75 38.6 ± 10.0 5.1 ± 0.6 464 ± 86 5.3 ± 1.0 0.142 ± 0.026
Standard female 120 72 ± 11 0.8 10 or 40 1.75 39.4 ± 12.4 4.8 ± 0.7 407 ± 73 4.6 ± 0.8 0.124 ± 0.028
Diagnostic
male
120 236 ± 86 0.6 20 or 40 1.375 116 ± 40.5 12.1 ± 2.8 1185 ± 249 17.4 ± 3.7 0.164 ± 0.063
Diagnostic
female
120 223 ± 109 0.6 20 or 40 1.375 122 ± 59.3 10.2 ± 3.9 912 ± 368 13.4 ± 5.5 0.121 ± 0.039
Data are the mean ± standard deviation
aEffective mAs is calculated as [(mA*tube rotation)/pitch]
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116 ± 40.5 mAs (50.0 to 231 mAs) for male patients and
121.6 ± 59.3 mAs (27.1 to 231 mAs) for female patients.
CT techniques are summarized in Table 2.
Radiation doses – 18F-FDG
The five organs with the highest organ equivalent doses
from 18F-FDG in all patients, in order of highest to
lowest dose, were bladder, heart, brain, liver and lungs.
18F-FDG organ equivalent doses are summarized in
Tables 3 and 4.
Mean ± SD (range) patient-specific effective dose
from 18F-FDG calculated by OLINDA for all patients
was 9.0 ± 1.6 mSv (3.4 to 13.6 mSv), 9.1 ± 1.7 mSv (5.4
to 12.8 mSv) for male and 10.0 ± 1.5 mSv (3.4 to
13.6 mSv) for female. Mean ± SD (range) effective dose
per unit injected activity for all patients was 0.0199 ±
0.0032 mSv/MBq (0.0132 to 0.0291 mSv/MBq). 18F-
FDG patient-specific effective doses are summarized in
Table 5.
Radiation doses - CT
The mean ± SD (range) effective dose for all patients
from the CT portion of scans employing the standard
technique was 5.0 ± 1.0 mSv (2.9 to 7.2 mSv), while it
was 15.4 ± 5.0 mSv (5.4 to 27.8 mSv) for the scans
employing a diagnostic technique.
The mean ± SD (range) effective dose per unit effective
mAs from all exams was 0.138 ± 0.046 mSv/mAs (0.036
to 0.445 mSv/mAs) for all patients, from standard CT
was 0.134 ± 0.028 mSv/mAs (0.067 to 0.185 mSv/mAs),
and from diagnostic CT was 0.142 ± 0.056 mSv/mAs
(0.036 to 0.445 mSv/mAs).
The mean ± SD (range) effective dose per unit dose-
length product (DLP) from all exams was 0.018 ±
0.046 mSv/mGy-cm (0.036 to 0.445 mSv/mGy-cm) for all
patients.
CT radiation doses are summarized in Table 6.
The five organs with the highest organ equivalent doses
from standard CT in all patients, in order of highest to
lowest dose, were thyroid, osteogenic cells, thymus, lungs
Table 3 Organ equivalent dose and effective dose from 18F-FDG PET/CT with standard CT to adult male and female patients
Organ Dose from 18F-FDG, mGya Dose from CT, mGyb Total dose, mGy
Male (n = 46) Female (n = 39) Male (n = 46) Female (n = 39) Male (n = 46) Female (n = 39)
Adrenals 5.1 ± 0.9 6.0 ± 1.0 5.3 ± 1.0 4.6 ± 0.8 10.4 ± 0.9 10.6 ± 0.9
Brain 15.9 ± 3.2 17.3 ± 3.2 6.0 ± 1.0 5.3 ± 0.9 21.9 ± 2.8 22.6 ± 2.9
Breasts 3.6 ± 0.7 4.3 ± 0.8 4.9 ± 0.9 4.2 ± 0.7 8.4 ± 0.8 8.5 ± 0.7
Gallbladder wall 5.4 ± 1.0 6.2 ± 1.8 5.6 ± 1.0 4.9 ± 0.9 11.1 ± 0.9 11.1 ± 1.0
Colon 4.9 ± 0.9 5.9 ± 1.0 5.2 ± 1.0 4.6 ± 0.8 10.2 ± 0.9 10.5 ± 0.9
Small intestine 5.1 ± 0.9 5.7 ± 1.0 5.2 ± 1.0 4.6 ± 0.8 10.3 ± 0.9 10.2 ± 0.9
Stomach wall 4.7 ± 0.9 5.6 ± 1.0 5.7 ± 1.0 4.9 ± 0.9 10.3 ± 0.9 10.5 ± 0.9
Heart wall 29.1 ± 6.2 35.4 ± 6.9 5.9 ± 1.1 5.2 ± 0.9 35.0 ± 5.6 40.6 ± 6.5
Kidneys 4.5 ± 0.8 5.3 ± 0.9 5.8 ± 1.1 5.1 ± 0.9 10.3 ± 0.9 10.3 ± 0.9
Liver 8.9 ± 1.7 11.0 ± 2.0 5.6 ± 1.0 4.8 ± 0.8 14.4 ± 1.4 15.8 ± 1.7
Lungs 8.3 ± 1.7 10.0 ± 1.8 6.3 ± 1.2 5.4 ± 1.0 14.6 ± 1.4 15.4 ± 1.5
Muscle 4.2 ± 0.8 5.0 ± 0.9 3.8 ± 0.7 3.3 ± 0.6 8.0 ± 0.7 8.3 ± 0.7
Ovaries/Testesc 4.6 ± 0.8 7.0 ± 1.2 1.1 ± 0.2 4.3 ± 0.8 5.6 ± 0.8 11.2 ± 1.0
Pancreas 5.2 ± 1.0 6.2 ± 1.0 5.2 ± 1.0 4.5 ± 0.8 10.4 ± 0.9 10.7 ± 0.9
Red marrow 4.2 ± 0.9 4.8 ± 1.0 4.4 ± 0.8 3.8 ± 0.7 8.5 ± 0.8 8.6 ± 0.9
Osteogenic cells 6.2 ± 1.8 67.4 ± 2.0 8.0 ± 1.6 6.9 ± 1.2 14.2 ± 1.5 14.3 ± 1.7
Skin 3.2 ± 0.6 3.7 ± 0.7 3.4 ± 0.6 3.0 ± 0.5 6.6 ± 0.6 6.7 ± 0.6
Spleen 4.4 ± 0.8 5.2 ± 0.9 5.4 ± 1.0 4.7 ± 0.8 9.8 ± 0.9 9.9 ± 0.9
Thymus 4.8 ± 0.9 5.7 ± 1.0 6.4 ± 1.2 5.6 ± 1.0 11.2 ± 1.0 11.3 ± 1.0
Thyroid 4.2 ± 0.8 4.4 ± 0.8 8.3 ± 1.4 7.3 ± 1.3 12.4 ± 1.2 11.7 ± 1.1
Urinary bladder wall 59.1 ± 5.2 79.5 ± 6.7 5.5 ± 1.0 4.8 ± 0.8 64.6 ± 4.8 84.3 ± 6.4
Uterus – 8.8 ± 1.4 – 4.6 ± 0.8 – 13.4 ± 1.2
Effective dosed 8.1 ± 1.2 10.1 ± 1.4 5.3 ± 1.0 4.6 ± 0.8 13.4 ± 1.1 14.7 ± 1.2
aPatient specific average dose calculated by OLINDA
bPatient specific average dose calculated by ImPACT
cOvaries for female patients/Testes for male patients
dEffective dose in mSv estimated by ICRP Publication 103
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and brain. CT organ equivalent doses are summarized in
Tables 3 and 4.
The five organs with the highest organ equivalent
doses from diagnostic CT in male patients, in order of
highest to lowest dose, were thyroid, osteogenic cells,
thymus, brain and lungs, and in female patients thyroid,
osteogenic cells, thymus, brain and heart.
Radiation doses – total dose
The mean ± SD (range) effective dose from the com-
bined PET and CT portions of all PET/CT exams was
19.6 ± 6.1 mSv (11.0 to 34.3 mSv) for all patients,
19.5 ± 2.3 mSv (11.0 to 31.1 mSv) for male patients
and 19.1 ± 3.1 mSv (12.8 to 34.3 mSv) for female
patients.
The mean ± SD (range) effective dose from the com-
bined PET and CT portions of the exams using standard
CT was 14.0 ± 1.3 mSv (11.0 to 17.6 mSv) for all
patients, 13.4 ± 1.1 mSv (11.0 to 16.2 mSv) for male
patients and 14.7 ± 1.2 mSv (12.8 to 17.6 mSv) for female
patients.
The mean ± SD (range) total effective dose from the
combined PET and CT portions of the exams using
diagnostic CT technique was 24.4 ± 4.3 mSv (14.6 to
Table 4 Organ equivalent dose and effective dose from 18F-FDG PET/CT with diagnostic CT to adult male and female patients
Organ Dose from 18F-FDGa Dose from CTb Total dose
Male (n = 49) Female (n = 49) Male (n = 49) Female (n = 49) Male (n = 49) Female (n = 49)
Adrenals 5.0 ± 0.6 5.9 ± 1.1 17.6 ± 3.7 13.5 ± 5.5 22.6 ± 3.4 19.4 ± 5.0
Brain 15.9 ± 2.1 16.6 ± 3.6 21.0 ± 4.4 16.1 ± 6.5 36.9 ± 3.6 32.8 ± 5.5
Breasts 3.6 ± 0.5 4.2 ± 0.9 15.7 ± 3.3 12.0 ± 4.8 19.3 ± 3.0 16.2 ± 4.4
Gallbladder wall 5.4 ± 0.7 6.0 ± 1.2 18.7 ± 3.9 14.4 ± 5.8 24.1 ± 3.1 20.4 ± 5.2
Colon 4.9 ± 0.6 5.8 ± 1.1 17.5 ± 3.7 13.5 ± 5.5 22.4 ± 3.4 19.3 ± 5.0
Small intestine 5.1 ± 0.6 5.6 ± 1.1 17.5 ± 3.7 13.5 ± 5.5 22.6 ± 3.4 19.1 ± 5.0
Stomach wall 4.7 ± 0.6 5.4 ± 1.1 18.6 ± 3.9 14.4 ± 5.8 23.3 ± 3.6 19.8 ± 5.3
Heart wall 29.0 ± 4.1 34.4 ± 7.7 20.0 ± 4.2 15.3 ± 6.2 48.9 ± 3.8 49.7 ± 6.4
Kidneys 4.4 ± 0.5 5.2 ± 1.0 19.1 ± 4.0 14.7 ± 6.0 23.5 ± 3.8 19.9 ± 5.5
Liver 8.9 ± 1.2 10.7 ± 2.2 17.9 ± 3.8 13.8 ± 5.6 26.8 ± 3.3 24.5 ± 4.7
Lungs 8.3 ± 1.1 9.8 ± 2.1 20.0 ± 4.2 15.3 ± 6.2 28.3 ± 3.7 25.1 ± 5.2
Muscle 4.2 ± 0.5 4.8 ± 1.0 12.5 ± 2.7 9.6 ± 3.9 16.7 ± 2.4 14.4 ± 3.4
Ovaries/Testesc 4.6 ± 0.6 6.8 ± 1.3 3.5 ± 0.7 12.6 ± 5.1 8.1 ± 0.6 19.4 ± 4.5
Pancreas 5.2 ± 0.6 6.1 ± 1.2 17.2 ± 3.6 13.2 ± 5.3 22.4 ± 3.3 19.3 ± 4.8
Red marrow 4.1 ± 0.6 4.7 ± 1.1 14.6 ± 3.0 11.2 ± 4.5 18.7 ± 2.7 15.9 ± 3.9
Osteogenic cells 6.1 ± 1.2 7.1 ± 2.1 26.4 ± 5.5 20.3 ± 8.2 32.6 ± 4.8 27.5 ± 7.0
Skin 3.2 ± 0.4 3.6 ± 0.7 11.1 ± 2.3 8.6 ± 3.4 14.2 ± 2.1 12.2 ± 3.1
Spleen 5.2 ± 1.08 5.1 ± 1.0 17.4 ± 3.7 13.4 ± 5.4 21.7 ± 3.4 18.5 ± 4.9
Thymus 4.4 ± 0.5 5.5 ± 1.1 21.8 ± 4.6 16.9 ± 6.8 26.6 ± 4.3 22.5 ± 6.2
Thyroid 4.2 ± 0.5 4.3 ± 0.9 28.0 ± 5.8 21.6 ± 8.7 32.2 ± 5.6 25.9 ± 8.2
Urinary bladder wall 59.1 ± 3.7 78.9 ± 9.2 18.5 ± 3.9 14.2 ± 5.7 77.7 ± 4.8 93.1 ± 10.2
Uterus - 8.6 ± 1.6 - 13.8 ± 5.8 - 22.4 ± 4.9
Effective dosed 8.1 ± 0.8 9.9 ± 1.6 17.4 ± 3.7 13.4 ± 5.5 25.5 ± 3.4 23.4 ± 4.9
aPatient specific average dose calculated by OLINDA
bPatient specific average dose calculated by ImPACT
cOvaries for female patients/Testes for male patients
dEffective dose estimated by ICRP publication 103
Table 5 18F-FDG Dose summary
CT technique description Injection activity (MBq) Effective dose (mSv) Effective dose per unit activity (mSv/MBq)
Male Female Male Female Male Female
Standard CT 455 ± 30 450 ± 26 8.1 ± 1.2 10.1 ± 1.4 0.018 ± 0.002 0.022 ± 0.002
Diagnostic CT 455 ± 25 454 ± 51 8.1 ± 0.8 9.9 ± 1.6 0.018 ± 0.002 0.022 ± 0.003
Data are the mean ± standard deviation. n, male standard CT=46. n, female standard CT = 39. n, male diagnostic CT = 49. n, female diagnostic CT = 49
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34.3 mSv) for all patients, 25.5 ± 3.4 mSv (17.8 to
31.1 mSv) for male patients and 23.4 ± 4.9 mSv (14.6 to
34.3 mSv) for female patients. Total doses are summa-
rized in Tables 7 and 8.
The five organs with the highest organ equivalent
doses from PET/CT in all patients, in order of highest
to lowest dose, were bladder, heart, brain, liver and
lungs. PET/CT organ equivalent doses are summarized
in Tables 3 and 4.
Discussion
Risk from radiation exposure to the individual patient is
important for evaluation of risk/benefit for justification,
and relevant to protocol optimization and personnel
protection [40]. The doses themselves utilized in the risk
estimation are useful for characterizing the patient
population and image acquisition practices of a clinic. A
dose estimation method can be based on a combination
of reference values and patient- and scanner-specific
data. Accurate estimation of patient dose, rather than a
conservatively high estimate, is important for many on-
cology patients who can potentially have many scans
and must track cumulative radiation exposure. The ac-
curacy of the patient dose used in the estimation of risk
depends on the dose estimation method employed: dose
estimated based on reference values depends on the
characteristics of the patient population in comparison
with the reference population, while the accuracy of the
dose estimated based on specific information depends
on the extent to which specific information is utilized.
Exam- and patient-specific factors are accounted for in
an ideal approach to dose estimation. In the current
study, we assessed radiation dosimetry of PET/CT for all
organs using patient- and exam-specific data and com-
monly available dosimetry resources.
Effective dose is commonly used when evaluating
relative biologic risk, and the Monte Carlo–based organ
dose coefficients should not be used to calculate effect-
ive dose for individual patients [6, 8]. The International
Organization for Medical Physics, ICRP, Health Physics
Society and American Association of Physicists in
Medicine (AAPM) all have issued policy statements that
note the dangers of extrapolating biological risk esti-
mates for radiation doses less than 100 mSv [6, 9–11].
The establishment and use of risk coefficients to esti-
mate public health determinants from individual or
population exposures must be considered in the context
of uncertainties in the estimates [12]. These uncertain-
ties include dosimetric uncertainties, epidemiological
and methodological uncertainties, uncertainties from
low statistical power and precision in epidemiology stud-
ies of radiation risk, uncertainties in modeling risk data,
generalization of risk estimates across different popula-
tions and dose rates, as well as reliance on epidemio-
logical studies on observational rather than experimental
data [13]. Uncertainties in such risk estimates have been
suggested as being up to a factor of 3 lower or higher
than the value itself [14]. These rather large uncertain-
ties cause predictions of radiation induced cancers or
detriment to be susceptible to biases and confounding
influences that are unidentifiable. With due recognition
of the limitations imposed by the uncertainties inherent
in correlating dose with risk, effective dose is a useful
approximation for relating patient population character-
istics and evaluating optimization efforts in addition to
the clinical benefits of exams.
For internal absorbed dose assessment, OLINDA\EXM
was used to perform dosimetry calculations for the vari-
ous body organs [32]. This code allows calculations for
814 radionuclides and a wide variety of adult, pediatric
and pregnant female phantoms; furthermore, it also
allows users to modify organ masses in the phantoms for
more patient-specific dose calculations. Organ doses cal-
culated by OLINDA\EXM based on reference phantoms




DLP mAs Effective dose Effective dose per unit mAs Effective dose per unit DLP
(mGy cm) (mAs) (mSv) (mSv/mAs) (mSv/mGy cm)
Standard 438 ± 84.8 39 ± 11 7.9 ± 1.5 0.134 ± 0.028 0.013 ± 0.002
Diagnostic 1050 ± 342 119 ± 51 15.4 ± 5.0 0.142 ± 0.056 0.015 ± 0.0002
Data are the mean ± standard deviation
Table 7 Effective dose for male and female patients
CT Technique
Description
18F-FDG PET CT Total
(mSv) (mSv) (mSv)
Male Female Male Female Male Female
Standard CT 8.1 ± 1.2 10.1 ± 1.4 5.3 ± 1.0 4.6 ± 0.8 13.4 ± 1.1 14.7 ± 1.2
Diagnostic CT 8.1 ± 0.8 9.9 ± 1.6 17.4. ± 3.7 13.4 ± 5.5 25.5 ± 3.4 23.4 ± 4.9
Data are the mean ± standard deviation
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representing the average patient were found to be in good
agreement with patient specific Monte Carlo mean dose
estimates [41]. Monte Carlo results suggest that the differ-
ence between the organ equivalent dose estimates in our
calculations and those derived from the use of earlier styl-
ized MIRD-type phantoms can be different by a margin as
great as 277 %[42]. Patient-specific organ masses were de-
rived from previous reports on variations in the mass of
different body organs in relation to stature and BMI ([37–
39]. Marine et al, and Clark et al described phantoms that
model different body types in a series of percentile height
phantoms to evaluate the variation of specific absorbed
fractions with height and weight differences across the hu-
man population [37, 39]. With patient-specific data and a
mean injected activity of 454 MBq, the mean effective
dose of 9.0 mSv is consistent with dose per unit injected
activity reported in the literature, and also with the dose
estimates from ICRP publication 106 [23, 25–28, 34]. The
relatively higher injected activity in our clinic at the time
of the study results in a relatively higher whole body dose
than is observed in other clinics with lower fixed standard
injection activity or body mass adjusted injection activity.
Despite a lack of 18F-FDG uptake in lung, this organ re-
ceived the third-highest organ dose according to our
methods, and this is most likely due to the proximity of
the lung to the heart. Injected activity, patient body mass
and height, all available from the patient record, were
among the specific factors employed in our estimation of
specific internal dose from 18F-FDG.
ImPACT Dose is a readily available CT organ dose cal-
culation tool that reports organ doses based on modeled
radiation transport data specific to the CT scanner and
represents improved accuracy over previous methods
[17]. Without using patient-specific inputs to ImPACT,
organ dose was overestimated by 17 %. A contributing
factor to this difference is likely the relatively larger size
of our patient population. The mean BMI of our patient
population was 26.4 while a reference BMI from ICRP
Reference Man characteristics is 23.5. It should be noted
that there is an opportunity to make the CT organ dose
estimate more specific than in our study. Because the
Dose Length Product (DLP) in the exam dose report is
itself a general value based on a single phantom, the
dose estimate may be made more specific by modifying
CTDIvol to account for patient size [43]. Scanner-
specific results such as the average scan length are useful
for identifying opportunities for optimization and for
evaluation against similar protocols and standards. For
example, the scan length for a whole-body PET/CT can
be compared to the scan length for a whole body CT at
the same clinic or to a reference value. The average ± SD
scan length of diagnostic whole body PET/CT in the
present study is 89.5 ± 14.7 cm, while the combined scan
length of chest + abdomen + pelvis CT scans is reported
as 73 cm [29]. Knowledge of the relative scan lengths
puts differences in dose and DLP in perspective. Further,
the anatomy in a diagnostic PET/CT is fixed to PET
anatomy selection, while the anatomy during the CT-
only acquisition may be optimally adjusted. Anatomy se-
lection, and avoidance, is an important aspect of CT
protocol optimization that may be overlooked for
incorporation into PET/CT scanners. Individual technol-
ogists may incorporate optimal anatomy selection in
both CT and PET/CT scans, but this optimization meas-
ure is more likely to be routinely incorporated as a
matter of policy for CT scanners than PET/CT scanners
utilized for diagnostic PET/CT exams. In these ways,
scanner-specific data are useful for characterizing the
clinic’s practices and identifying opportunities for
optimization.
Although the average diagnostic PET/CT scan length
in this study is greater than that reported in the litera-
ture, the dose from the CT portion of the diagnostic
PET/CT exams we evaluated in this study is consistent
with the average whole body CT dose reported in the
literature. Table 9 summarizes doses reported in the litera-
ture for whole body CT and chest-abdomen-pelvis (CAP)
CT exams, which have approximately the same length
scans as whole body PET/CT scans [22, 24, 29–31].
The average value of the five included studies report-
ing whole-body or equivalent CT dose is 15.1 mSv and
likely represents a conservative estimate of average dose
from a whole body diagnostic CT. A clear advantage of a
combined diagnostic PET/CT is the higher patient
throughput relative to separate scheduling, along with a
relatively shorter exam time than the lower-dose alterna-
tives. From the patient’s perspective, a single visit to the
imaging clinic is easier than two separate visits. If the
doses are the same, then a combined scan has the
additional patient benefit convenience. Depending on
the contributing factors at a given imaging clinic, the
radiation dose from a standard PET/CT with separate
Table 9 Comparison of reported whole body diagnostic CT
effective dose
CT study 1a 2b 3c 4d 5e Average This study
Effective dose (mSv) 19 9.25 12.5 22.5 16 15.1 15.4
Data are mean mSv
aCT-based transmission scan in high quality mode [31]
b73-cm CAP CT [29]
cWhole body CT, C3 to symphisis pubis [22]
dComplete whole body CT includes thyroid contribution [24]
eBased on UK survey of CAP CT [30]
Table 8 Effective dose summary for all patients
CT technique description 18F-FDG PET CT Total
Standard CT 9.0 ± 1.6 5.0 ± 1.0 14.0 ± 1.3
Diagnostic CT 9.0 ± 1.6 15.4 ± 5.0 24.4 ± 4.3
Data are the mean ± standard deviation in mSv
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diagnostic CT may be more or less than the radiation
dose from a diagnostic PET/CT. Intuitively, a PET/CT with
diagnostic technique compared to a standard PET/CT
with separately acquired diagnostic CT may appear to be
qualitatively equivalent but dosimetrically different be-
cause the PET/CT with diagnostic technique CT can also
be used for attenuation correction. CT dose from the
standard PET/CT appears to be in addition to the dose
from the separate diagnostic CT. However, differences in
PET/CT and CT scanner hardware and software can cause
the dose to be higher or lower. For example, the number
of slices is typically different between dual- and single-
modality units, and adaptive filtering may not available on
PET/CT machines. Both hardware and software factors
can cause the patient dose from a combined scan to be
higher or lower than separately acquired scans and must
be considered when evaluating the dose at a given clinic
with reference or literature doses. Less variation is ob-
served in reported PET dose that is estimated from a sin-
gle source, such as ICRP 106. Even the standards at an
imaging clinic for uptake time and acquisition time can
affect dose by influencing injected activity. A busy clinic
with a fixed injected activity per patient, for example, may
administer relatively more activity to account for the inev-
itable changes in scheduling that come with patient can-
cellations, delays and other impacts on timing. There is
evidence, however, that weight- or BMI-adjusted injected
activity reduces patient dose and staff exposure without
compromising image quality [44]. A busy clinic may also
benefit from a relatively higher injected activity to shorten
the acquisition time, as PET acquisition is based on total
counts in a bed field and more activity results in the total
counts achieved relatively sooner.
The potential for variation in reported dose from PET
is apparent in the variability in those PET exam parame-
ters that depend on clinical setting. The patient dose in a
clinic employing Germanium-based attenuation correction
will differ from a clinic that uses CT-based attenuation
correction. Germanium-based attenuation correction has
been found to result in negligible patient dose, but it also
results in lower diagnostic value in terms of anatomical
delineation and longer scanning time than CT-based
attenuation correction [31]. The additional challenge of
coregistering separate image sets also accompanies this
approach. Nonetheless, Germanium-based attenuation
correction is sufficient for standard PET/CT exams and
still finds routine usage amongst clinics that wish to add
PET imaging, but already have a CT scanner. The possibil-
ity of different attenuation correction methods makes a
one-size-fits-all estimate of expected radiation dose for
PET/CT exams unrealistic, and promotes a specific ap-
proach to dose evaluation.
Brix et al evaluated total dose from PET/CT exams
utilizing CT-based attenuation correction at different
hospitals and demonstrated that regardless of whether
the PET/CT protocol is standard or diagnostic, the dose
from a PET/CT exam is about 23 mSv, due to different
approaches, hardware, standards and clinical objectives
[23]. RPOP reference doses are compared with the re-
sults of our study and with typical literature data in
Table 10.
The range of doses observed in Table 10 demonstrates
the importance of careful choice of data, characterizing
the dose at one’s own clinic and understanding the fac-
tors contributing to patient dose from PET/CT.
Dose estimated using reference values and standard
body models requires the least amount of effort and
results in a non-specific estimate that may not be con-
sistent with the characteristics of the actual patient
population. However, many exam-specific parameters
are conveniently accessed with minimal effort. Reference
DLP values are available, but in practice the actual DLP
from the exam is readily available from the dose report
and is easily used to estimate effective dose by employ-
ing either a standard or scanner-specific factor [18]. An
approach employing all available patient-specific re-
sources (i.e. patient-adjusted DLP and organ mass,
scanner-specific factors) results in accurate estimation
but requires moderate effort because this data must be
retrieved from electronic records. A retrospective dose
estimate requires accessing DICOM information and pa-
tient records for relevant information, while estimating
dose from a present exam for an individual patient can
utilize information at hand. Whether the risk estimate is
made at the time of the exam or retrospectively, and
whether it is for an individual or representative group,
the effort involved in gathering the information must be
weighed against the value of the information gained.
Conclusions
An ideal dose estimation method is convenient to em-
ploy and considers clinic- and patient-specific factors to
an appropriate extent. Patient specific parameters (e.g.,
weight, and height) identified from patient data allow for
more accurate estimate of organ equivalent doses and
the effort involved in obtaining the data is worthwhile
Table 10 Comparison of reference dose with our results and
literature
RPOP This study Literaturea
Injected activity (MBq) 400 454 370
PET dose 8 9 7
Standard CT dose 7 5 2.7
Diagnostic CT dose 30 15.4 16.1
Total dose, standard PET/CT 15 14 9.7
Total dose, Diagnostic PET/CT 38 24.4 23.1
Note: doses are in mSv. aBrix et al [23]
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for a retrospective analysis of a representative patient
sample and for some individual patients. Accurate esti-
mation of patient dose, rather than a conservatively high
estimate, is important for many oncology patients who
can potentially have many scans and must track cumula-
tive exposure. Considering actual patient-specific charac-
teristics resulted in lower organ equivalent dose estimates
than traditional reference phantoms and models, but the
methods employed in this study resulted in organ doses
and effective doses that are in agreement with alternative
methods. Considering the substantial radiation dose of
whole body PET/CT exams and the potential for wide
variation in contributing factors, all aspects of the exam
process should be considered for optimization. Radiophar-
maceutical injection activity, CT technique, CT protocol
optimization measures, anatomy selection, and con-
venience to both patient and imaging clinic are all
factors which must be considered for comprehensive
optimization and subsequent justification of the PET/CT
exam. The effort involved in obtaining patient-specific
data is reasonable to help justify the risk associated with
the radiation exposure, optimize the image acquisition pa-
rameters to balance dose with the objectives of the exam,
and characterize the patient population.
Clinic-specific patient dose for each type of PET/CT
exam can reasonably be estimated for comparison with
industry standards, reference values and literature values.
Opportunities for optimization may also be apparent in
better understanding how the clinic’s doses compare with
other sources of data.
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